Technical Analysis for CNCR - Loncar Cancer Immunotherapy ETF

Grade Last Price % Change Price Change
D 13.67 1.22% 0.17
CNCR closed up 1.22 percent on Monday, July 1, 2024, on 33 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
Bullish Engulfing Bullish 0.00%
Crossed Above 200 DMA Bullish 0.00%
Stochastic Buy Signal Bullish 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 200 DMA Bearish 1.22%
Hammer Candlestick Bullish 1.22%
Lizard Bullish Bullish Day Trade Setup 1.22%
Narrow Range Bar Range Contraction 1.22%
Gapped Down Weakness 1.22%

   Recent Intraday Alerts

Alert Time
Lizard Bullish Entry about 8 hours ago
Hammer Candlestick Entry about 8 hours ago
Rose Above Previous Day's High about 8 hours ago
Rose Above 200 DMA about 8 hours ago
Possible NR7 3 days ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Loncar Cancer Immunotherapy ETF Description

ETF Series Solutions - Loncar Cancer Immunotherapy ETF is an exchange traded fund launched by ETF Series Solutions. The fund is co-managed by Exchange Traded Concepts, LLC and Vident Investment Advisory, LLC. It invests in public equity markets of the United States. The fund invests in stocks of companies operating in the pharmaceutical or biotechnology sectors, including those companies identified as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. It invests in stocks of companies across all market capitalizations. The fund seeks to replicate the performance of the Loncar Cancer Immunotherapy Index, by investing in stocks of companies as per their weightings in the index. ETF Series Solutions - Loncar Cancer Immunotherapy ETF is domiciled in the United States.


Classification

Keywords: Exchange Traded Fund ETF Exchange Traded Funds Biotechnology SPDR Cancer Betashares Immune System Immunotherapy Cancer Immunotherapy Biotechnology Sectors Lonca

Top 10 Components

Symbol Grade Price % Change Allocation
GERN B 2.36 3.93
ELVN B -2.87 3.15
SMMT B 4.36 2.57
NRIX B 0.19 2.29
ITOS C 1.15 2.24
NUVB C 8.22 2.15
MRUS B -7.98 2.09
BPMC A 1.30 1.92
RVMD C 0.00 1.87
ACRV F 1.03 1.76

Is CNCR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 17.9599
52 Week Low 9.22
Average Volume 8,942
200-Day Moving Average 13.54
50-Day Moving Average 14.60
20-Day Moving Average 14.18
10-Day Moving Average 13.74
Average True Range 0.30
RSI (14) 40.12
ADX 17.25
+DI 24.86
-DI 38.87
Chandelier Exit (Long, 3 ATRs) 14.12
Chandelier Exit (Short, 3 ATRs) 14.31
Upper Bollinger Bands 15.12
Lower Bollinger Band 13.23
Percent B (%b) 0.23
BandWidth 13.37
MACD Line -0.33
MACD Signal Line -0.29
MACD Histogram -0.0402
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.93
Resistance 3 (R3) 13.90 13.78 13.88
Resistance 2 (R2) 13.78 13.72 13.80 13.87
Resistance 1 (R1) 13.73 13.68 13.76 13.76 13.85
Pivot Point 13.61 13.61 13.63 13.63 13.61
Support 1 (S1) 13.56 13.55 13.59 13.59 13.49
Support 2 (S2) 13.44 13.51 13.46 13.47
Support 3 (S3) 13.39 13.44 13.46
Support 4 (S4) 13.42